Sabra Health Care REIT - SBRA Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $15.27
  • Forecasted Upside: 9.77%
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$13.91
▲ +0.11 (0.80%)

This chart shows the closing price for SBRA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sabra Health Care REIT Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SBRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SBRA

Analyst Price Target is $15.27
▲ +9.77% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Sabra Health Care REIT in the last 3 months. The average price target is $15.27, with a high forecast of $21.00 and a low forecast of $12.50. The average price target represents a 9.77% upside from the last price of $13.91.

This chart shows the closing price for SBRA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 12 polled investment analysts is to moderate buy stock in Sabra Health Care REIT. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
8/30/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
11/28/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
2/26/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
5/27/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
8/25/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
11/23/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
1/22/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
2/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/30/2024Deutsche Bank AktiengesellschaftInitiated CoverageBuy$21.00Low
1/3/2024MizuhoBoost TargetBuy ➝ Buy$15.00 ➝ $17.00Low
11/7/2023Stifel NicolausBoost TargetBuy ➝ Buy$14.00 ➝ $16.00Low
10/17/2023BMO Capital MarketsReiterated RatingOutperform ➝ Market Perform$16.00Low
10/16/2023Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$13.00 ➝ $15.00Low
10/10/2023Bank of AmericaUpgradeNeutral ➝ Buy$14.00 ➝ $16.00Low
10/3/2023WedbushInitiated CoverageOutperform$16.00Low
9/29/2023Truist FinancialBoost Target$13.00 ➝ $15.00Low
9/20/2023Jefferies Financial GroupUpgradeHold ➝ Buy$11.00 ➝ $15.00Low
8/11/2023Bank of AmericaUpgradeUnderperform ➝ Neutral$11.00 ➝ $14.00Low
7/27/2023Berenberg BankInitiated CoverageHold$13.00Low
7/14/2023CitigroupBoost TargetNeutral$11.00 ➝ $12.50Low
5/4/2023Stifel NicolausLower Target$15.00 ➝ $14.00Low
4/25/2023BarclaysLower Target$15.00 ➝ $13.00Low
4/19/2023Wells Fargo & CompanyInitiated CoverageUnderweight$11.00Low
4/12/2023Credit Suisse GroupReiterated RatingNeutral$13.00Low
3/29/2023Truist FinancialLower TargetBuy$14.00 ➝ $13.00Low
3/28/2023CitigroupLower TargetNeutral$13.00 ➝ $10.50Low
12/13/2022JMP SecuritiesDowngradeOutperform ➝ Market PerformLow
11/14/2022Bank of AmericaDowngradeNeutral ➝ Underperform$15.00 ➝ $13.00Low
10/10/2022Robert W. BairdDowngradeOutperform ➝ Neutral$13.00Low
8/22/2022CitigroupBoost Target$15.50Low
8/9/2022BarclaysBoost Target$15.00Low
6/30/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$15.00 ➝ $14.00Low
6/3/2022Capital One FinancialInitiated CoverageEqual Weight ➝ Equal Weight$15.50Low
5/25/2022MizuhoUpgradeNeutral ➝ Buy$16.00 ➝ $15.00High
4/18/2022BarclaysDowngradeOverweight ➝ Equal Weight$16.00 ➝ $14.00High
4/4/2022Credit Suisse GroupBoost TargetNeutral$14.00 ➝ $15.00High
3/11/2022Bank of AmericaUpgradeUnderperform ➝ Neutral$15.00Low
2/23/2022Stifel NicolausLower TargetBuy$21.00 ➝ $18.00High
2/22/2022BarclaysLower Target$19.00 ➝ $16.00High
2/18/2022KeyCorpInitiated CoverageSector Weight ➝ Sector WeightLow
2/15/2022JMP SecuritiesLower TargetBuy$20.00 ➝ $16.00Medium
2/1/2022Credit Suisse GroupInitiated CoverageNeutral$14.00Medium
1/20/2022MizuhoLower Target$18.00 ➝ $16.00High
10/7/2021Robert W. BairdInitiated CoverageOutperform$18.00Low
9/30/2021Truist FinancialUpgradeHold ➝ Buy$18.00High
9/13/2021JMP SecuritiesLower TargetMarket Outperform$24.00 ➝ $20.00Low
5/21/2021BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$20.00 ➝ $21.00Low
5/9/2021Stifel NicolausUpgradeHold ➝ Buy$17.00 ➝ $21.00Low
1/13/2021MizuhoDowngradeBuy ➝ Neutral$18.00Low
1/13/2021Jefferies Financial GroupUpgradeHold ➝ Buy$17.00 ➝ $20.00Low
1/7/2021BMO Capital MarketsUpgradeUnderperform ➝ Market Perform$19.00Low
12/15/2020Smith Barney CitigroupBoost Target$14.00 ➝ $17.00Medium
12/3/2020JMP SecuritiesUpgradeMarket Perform ➝ Outperform$24.00Medium
10/2/2020MizuhoBoost TargetBuy$14.00 ➝ $16.00High
9/1/2020Stifel NicolausReiterated RatingHold$15.00High
7/2/2020CitigroupBoost TargetNeutral$10.00 ➝ $14.00Low
6/23/2020ScotiabankUpgradeSector Underperform ➝ Sector Perform$12.00 ➝ $15.00Medium
6/22/2020Wells Fargo & CompanyBoost TargetEqual Weight$13.00 ➝ $14.00Low
6/8/2020JMP SecuritiesInitiated CoverageMarket PerformLow
5/18/2020Berenberg BankUpgradeHold ➝ Buy$15.00High
4/23/2020SunTrust BanksReiterated RatingHold$15.00Medium
4/7/2020CitigroupLower TargetNeutral$20.00 ➝ $10.00High
3/26/2020Wells Fargo & CompanyLower TargetEqual Weight$22.00 ➝ $10.50Medium
3/23/2020Bank of AmericaDowngradeNeutral ➝ UnderperformMedium
2/26/2020MizuhoUpgradeNeutral ➝ Buy$22.00Low
2/6/2020BarclaysLower TargetOverweight$26.00 ➝ $25.00Low
2/5/2020Berenberg BankInitiated CoverageHold$22.00Medium
12/19/2019MizuhoInitiated CoverageNeutral$22.00Medium
12/18/2019CitigroupUpgradeSell ➝ Neutral$20.00High
10/14/2019Bank of AmericaInitiated CoverageNeutralLow
9/27/2019JMP SecuritiesBoost TargetMarket Outperform$22.00 ➝ $23.00Low
9/23/2019CitigroupDowngradeNeutral ➝ Sell$18.00 ➝ $20.00Low
9/3/2019BarclaysInitiated CoverageOverweight$24.00High
2/26/2019BMO Capital MarketsDowngradeMarket Perform ➝ UnderperformMedium
(Data available from 2/21/2019 forward)

News Sentiment Rating

1.47 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 14 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/26/2023
  • 10 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/25/2023
  • 13 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/24/2023
  • 8 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2023
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/23/2023
  • 7 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/23/2023
  • 11 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/22/2024
  • 15 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2024

Current Sentiment

  • 15 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Sabra Health Care REIT logo
As of September 30, 2023, Sabra's investment portfolio included 377 real estate properties held for investment (consisting of (i) 240 Skilled Nursing/Transitional Care facilities, (ii) 43 senior housing communities (Senior Housing - Leased), (iii) 61 senior housing communities operated by third-party property managers pursuant to property management agreements (Senior Housing - Managed), (iv) 18 Behavioral Health facilities and (v) 15 Specialty Hospitals and Other facilities), 12 investments in loans receivable (consisting of two mortgage loans and 10 other loans), five preferred equity investments and two investments in unconsolidated joint ventures. As of September 30, 2023, Sabra's real estate properties held for investment included 37,606 beds/units, spread across the United States and Canada.
Read More

Today's Range

Now: $13.91
Low: $13.77
High: $13.92

50 Day Range

MA: $13.85
Low: $12.91
High: $14.57

52 Week Range

Now: $13.91
Low: $10.08
High: $14.82

Volume

89,611 shs

Average Volume

2,038,781 shs

Market Capitalization

$3.22 billion

P/E Ratio

N/A

Dividend Yield

8.73%

Beta

1.14

Frequently Asked Questions

What sell-side analysts currently cover shares of Sabra Health Care REIT?

The following Wall Street research analysts have issued stock ratings on Sabra Health Care REIT in the last twelve months: Bank of America Co., Barclays PLC, Berenberg Bank, BMO Capital Markets, Citigroup Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., Mizuho, Stifel Nicolaus, StockNews.com, Truist Financial Co., Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for SBRA.

What is the current price target for Sabra Health Care REIT?

13 Wall Street analysts have set twelve-month price targets for Sabra Health Care REIT in the last year. Their average twelve-month price target is $15.27, suggesting a possible upside of 10.6%. Deutsche Bank Aktiengesellschaft has the highest price target set, predicting SBRA will reach $21.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $12.50 for Sabra Health Care REIT in the next year.
View the latest price targets for SBRA.

What is the current consensus analyst rating for Sabra Health Care REIT?

Sabra Health Care REIT currently has 5 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SBRA.

What other companies compete with Sabra Health Care REIT?

How do I contact Sabra Health Care REIT's investor relations team?

Sabra Health Care REIT's physical mailing address is 18500 VON KARMAN AVENUE SUITE 550, IRVINE CA, 92612. The real estate investment trust's listed phone number is (888) 393-8248 and its investor relations email address is [email protected]. The official website for Sabra Health Care REIT is www.sabrahealth.com. Learn More about contacing Sabra Health Care REIT investor relations.